AI Devices in Neurology-Moving From Diagnosis to Prognosis

JAMA Neurol. 2024 Nov 18. doi: 10.1001/jamaneurol.2024.3835. Online ahead of print.

Authors

James M Hillis^{1

2}, Edward R Scheffer Cliff^{2

3}, Kerstin N Vokinger^{4

5}

Affiliations

¹ Department of Neurology, Massachusetts General Hospital, Boston.
² Harvard Medical School, Boston, Massachusetts.
³ Program on Regulation, Therapeutics and Law, Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts.
⁴ Faculty of Law, University of Zurich, Zurich, Switzerland.
⁵ Department of Health Sciences and Technology, ETH Zurich, Zurich, Switzerland.

PMID: 39556390
DOI: 10.1001/jamaneurol.2024.3835

No abstract available

Plain language summary

This Viewpoint describes considerations for regulatory oversight in the implementation of artificial intelligence–enabled prognostic devices.